ArticleBMC cancer2016

PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).

Thomas Grellety et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.